Lifeloc Technologies Q2 net loss narrows on high research and development investment; gross margin improves

Lifeloc Technologies

13/08/2026 21:27

Overview
U.S. breathalyzer maker's Q2 revenue rose 10% yr/yr
Q2 net loss narrowed from prior year as gross margin improved to 45%
Company secured $500,000 loan from Chairman and CFO during quarter

Outlook
Company targets limited commercial launch of SpinDetect analyzer in Q1 2027
Company expects to expand SpinDetect platform to additional drug panels and applications

Result Drivers
PRICE INCREASES AND PRODUCT MIX - Co said higher gross margin was driven by price increases and a favorable product mix
R&D SPENDING - Co said continued high research and development investment, mainly for SpinDetect analyzer development, contributed to the net loss
PRODUCT LINE STRENGTH - Co said its core alcohol detection products and new L-series devices supported market penetration and incremental sales

Company press release: ID:nACSh931Sa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$2.45 mln
 
Q2 Loss Per Share
 
$0.05
 
Q2 Net Loss
 
$134,000
 
Q2 Gross Margin
 
45.00%
 

Reuters Recommended Reads
Aug 11 - 908 Devices Q2 revenue beats on increased VipIR sales
Aug 11 - Velo3D Q2 revenue beats estimates on higher prices, product mix; lifts 2026 outlook
Aug 11 - Evolv Technologies raises 2026 outlook after Q2 revenue beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)